Allianz Asset Management’s Pacific Biosciences PACB Stock Holding History

Allianz Asset Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-50,096	Closed	-$1.02M	–	2593
2021 Q4	$1.02M	Sell	50,096 -7,881	-14%	-$190K	﹤0.01%	1900
2021 Q3	$1.48M	Buy	57,977 +41,450	+251%	+$1.23M	﹤0.01%	1766
2021 Q2	$578K	Sell	16,527 -45,191	-73%	-$1.31M	﹤0.01%	1979
2021 Q1	$2.06M	Sell	61,718 -21,462	-26%	-$751K	﹤0.01%	1398
2020 Q4	$2.16M	Sell	83,180 -84,500	-50%	-$1.44M	﹤0.01%	1294
2020 Q3	$1.66M	Buy	+167,680	New	+$965K	﹤0.01%	1313
2019 Q1	–	Sell	-461,225	Closed	-$3.41M	–	2755
2018 Q4	$3.41M	Buy	+461,225	New	+$2.92M	﹤0.01%	1566
2017 Q2	–	Sell	-396,075	Closed	-$2.05M	–	2668
2017 Q1	$2.05M	Sell	396,075 -22,000	-5%	-$108K	﹤0.01%	1992
2016 Q4	$1.59M	Sell	418,075 -175,031	-30%	-$1.27M	﹤0.01%	2049
2016 Q3	$5.31M	Buy	+593,106	New	+$4.96M	0.01%	1593

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Allianz Asset Management's PACB Position: Q1 2022 in Review

Allianz Asset Management sold out of Pacific Biosciences (PACB) in Q1 2022, closing a stake of 50,096 shares — an estimated $1.02M sold.

Allianz Asset Management first reported a position in PACB in Q3 2016 and held it in 10 quarters. The position peaked at $5.31M in Q3 2016. 249 funds tracked by Wall St. Rank hold PACB as of Q1 2022.

Allianz Asset Management reported no remaining Pacific Biosciences position as of Q1 2022 after selling out during the quarter.
Allianz Asset Management sold 50,096 Pacific Biosciences shares in Q1 2022, an estimated $1.02M.
Allianz Asset Management first reported a position in Pacific Biosciences in Q3 2016 and held it in 10 quarters.
Allianz Asset Management's Pacific Biosciences position peaked at $5.31M in Q3 2016.
249 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2022.

Based on Allianz Asset Management's 13F filing for Q1 2022, filed 13 May 2022.